Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

168. Statins for primary and secondary prevention of cardiovascular disease

Statins for primary and secondary prevention of cardiovascular disease

DynaMed Plus2017

172. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.

Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. BACKGROUND: Pharmacologic inhibitors of proprotein convertase subtilisin-kexin type 9 (PCSK9) are being evaluated in clinical trials for the treatment of cardiovascular disease. The effect of lowering low-density lipoprotein (LDL) cholesterol levels by inhibiting PCSK9 on the risk of cardiovascular events or diabetes is unknown. METHODS: We used genetic scores consisting of independently inherited variants (...) in the genes encoding PCSK9 and 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR; the target of statins) as instruments to randomly assign 112,772 participants from 14 studies, with 14,120 cardiovascular events and 10,635 cases of diabetes, to groups according to the number of LDL cholesterol-lowering alleles that they had inherited. We compared the effects of lower LDL cholesterol levels that were mediated by variants in PCSK9, HMGCR, or both on the risk of cardiovascular events and the risk

NEJM2016

173. Twitter as a potential data source for cardiovascular disease research

Twitter as a potential data source for cardiovascular disease research 27680322 2018 11 13 2380-6591 1 9 2016 Dec 01 JAMA cardiology JAMA Cardiol Twitter as a Potential Data Source for Cardiovascular Disease Research. 1032-1036 10.1001/jamacardio.2016.3029 As society is increasingly becoming more networked, researchers are beginning to explore how social media can be used to study person-to-person communication about health and health care use. Twitter is an online messaging platform used (...) by more than 300 million people who have generated several billion Tweets, yet little work has focused on the potential applications of these data for studying public attitudes and behaviors associated with cardiovascular health. To describe the volume and content of Tweets associated with cardiovascular disease as well as the characteristics of Twitter users. We used Twitter to access a random sample of approximately 10 billion English-language Tweets originating from US counties from July 23, 2009

JAMA cardiology2016 Full Text: Link to full Text with Trip Pro

174. New guidelines and evidence for prevention and treatment of dyslipidemia and atherosclerotic cardiovascular disease in China

New guidelines and evidence for prevention and treatment of dyslipidemia and atherosclerotic cardiovascular disease in China 29063058 2018 11 13 2095-882X 3 2 2017 Jun 25 Chronic diseases and translational medicine Chronic Dis Transl Med New guidelines and evidence for prevention and treatment of dyslipidemia and atherosclerotic cardiovascular disease in China. 73-74 10.1016/j.cdtm.2016.11.001 Hu Da-Yi DY Peking University People's Hospital Cardiovascular Institute, Beijing 100044, China. eng (...) Editorial 2016 11 26 China Chronic Dis Transl Med 101679934 2095-882X Zhonghua Xin Xue Guan Bing Za Zhi. 2016 Oct 24;44(10 ):833-853 27903370 Atherosclerotic cardiovascular disease Dyslipidemia Guideline 2016 11 03 2017 10 25 6 0 2017 10 25 6 0 2017 10 25 6 1 epublish 29063058 10.1016/j.cdtm.2016.11.001 S2095-882X(16)30105-0 PMC5627699

Chronic diseases and translational medicine2016 Full Text: Link to full Text with Trip Pro

175. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. Importance: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States, accounting for 1 of every 3 deaths among adults. Objective: To update the 2008 US Preventive Services Task Force (USPSTF) recommendation on screening for lipid disorders in adults. Evidence Review: The USPSTF reviewed the evidence on the benefits

JAMA2016

176. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update 27697765 2016 10 04 2016 12 12 1468-2060 76 1 2017 Jan Annals of the rheumatic diseases Ann. Rheum. Dis. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. 17-28 10.1136/annrheumdis-2016-209775 Patients (...) with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates

EvidenceUpdates2016

177. Effect of Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease Patients with Nonsleepy Obstructive Sleep Apnea. The RICCADSA Randomized Controlled Trial

Effect of Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease Patients with Nonsleepy Obstructive Sleep Apnea. The RICCADSA Randomized Controlled Trial 26914592 2016 09 02 2016 09 02 1535-4970 194 5 2016 Sep 01 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. Effect of Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease Patients with Nonsleepy Obstructive Sleep Apnea. The RICCADSA Randomized (...) Controlled Trial. 613-20 10.1164/rccm.201601-0088OC Obstructive sleep apnea (OSA) is common in patients with coronary artery disease (CAD), many of whom do not report daytime sleepiness. First-line treatment for symptomatic OSA is continuous positive airway pressure (CPAP), but its value in patients without daytime sleepiness is uncertain. To determine the effects of CPAP on long-term adverse cardiovascular outcome risk in patients with CAD with nonsleepy OSA. This single-center, prospective, randomized

EvidenceUpdates2016

178. Potential Strategies to Address the Major Clinical Hurdles Facing Stem Cell Regenerative Therapy for Cardiovascular Disease: A Review

Potential Strategies to Address the Major Clinical Hurdles Facing Stem Cell Regenerative Therapy for Cardiovascular Disease: A Review 27579998 2018 09 17 2018 11 13 2380-6591 1 8 2016 11 01 JAMA cardiology JAMA Cardiol Potential Strategies to Address the Major Clinical Barriers Facing Stem Cell Regenerative Therapy for Cardiovascular Disease: A Review. 953-962 10.1001/jamacardio.2016.2750 Although progress continues to be made in the field of stem cell regenerative medicine for the treatment (...) of cardiovascular disease, significant barriers to clinical implementation still exist. To summarize the current barriers to the clinical implementation of stem cell therapy in patients with cardiovascular disease and to discuss potential strategies to overcome them. Information for this review was obtained through a search of PubMed and the Cochrane database for English-language studies published between January 1, 2000, and July 25, 2016. Ten randomized clinical trials and 8 systematic reviews were included

JAMA cardiology2016 Full Text: Link to full Text with Trip Pro

179. Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology.

Lack of Evidence Linking Calcium With or Without Vitamin D Supplementation to Cardiovascular Disease in Generally Healthy Adults: A Clinical Guideline From the National Osteoporosis Foundation and the American Society for Preventive Cardiology. Description: Calcium is the dominant mineral present in bone and a shortfall nutrient in the American diet. Supplements have been recommended for persons who do not consume adequate calcium from their diet as a standard strategy for the prevention (...) of osteoporosis and related fractures. Whether calcium with or without vitamin D supplementation is beneficial or detrimental to vascular health is not known. Methods: The National Osteoporosis Foundation and American Society for Preventive Cardiology convened an expert panel to evaluate the effects of dietary and supplemental calcium on cardiovascular disease based on the existing peer-reviewed scientific literature. The panel considered the findings of the accompanying updated evidence report provided

Annals of Internal Medicine2016

180. Risk stratification of atherosclerotic cardiovascular disease in Chinese adults

Risk stratification of atherosclerotic cardiovascular disease in Chinese adults 29063030 2018 11 13 2095-882X 2 2 2016 Jun Chronic diseases and translational medicine Chronic Dis Transl Med Risk stratification of atherosclerotic cardiovascular disease in Chinese adults. 102-109 10.1016/j.cdtm.2016.10.001 This study aims to determine the distribution of observed atherosclerotic cardiovascular disease (ASCVD) incidence in contemporary cohorts in China, and to identify cut-off points for ASCVD (...) of Epidemiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. Chen Ji-Chun JC Department of Epidemiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China. Li Jian-Xin JX Department of Epidemiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences

Chronic diseases and translational medicine2016 Full Text: Link to full Text with Trip Pro